Skip to main content
Clinical Trials/NCT05090813
NCT05090813
Completed
Not Applicable

A Real-World Study Evaluating Clinical Outcomes in China for the TECNIS Eyhance™ Intraocular Lens Model ICB00

Johnson & Johnson Surgical Vision, Inc.1 site in 1 country24 target enrollmentDecember 24, 2021
ConditionsCataracts

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cataracts
Sponsor
Johnson & Johnson Surgical Vision, Inc.
Enrollment
24
Locations
1
Primary Endpoint
percentage of eyes that achieve 0.3 ,0.2, 0.1 and 0.0 logMAR monocular DCIVA
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

This is a prospective and retrospective, single-center, single-arm, open-label clinical study of the TECNIS Eyhance™ IOL. The study will enroll up to 100 subjects from a single site in China. All subjects will be followed for 12 months postoperatively.

Registry
clinicaltrials.gov
Start Date
December 24, 2021
End Date
April 22, 2024
Last Updated
11 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female patients at least 22 years of age
  • Have/had a cataract in one or both eyes, with planned phacoemulsification with intraocular lens implantation or a history of implantation with TECNIS Eyhance intraocular lens
  • Availability, willingness and sufficient cognitive awareness to understand the purpose of the examination procedures and comply with study visits
  • Voluntary participation indicated by the study informed consent form (ICF) signed by the patient or legal guardian.

Exclusion Criteria

  • Concurrent participation or participation in any other clinical study within 30 days prior to the preoperative visit
  • Planned monovision correction (one eye designated for near correction).
  • Any other systemic or ocular disease that, in the opinion of the investigator, may affect the patient's eligibility for the study, affect visual acuity or may require surgical intervention during the course of the study (e.g., macular degeneration, cystoid macular edema, diabetic retinopathy, etc.).

Outcomes

Primary Outcomes

percentage of eyes that achieve 0.3 ,0.2, 0.1 and 0.0 logMAR monocular DCIVA

Time Frame: 6 months

mean monocular postoperative DCIVA

Time Frame: 6 months

Study Sites (1)

Loading locations...

Similar Trials